Quantcast
Last updated on April 24, 2014 at 11:28 EDT

Dr. Li Qun Joins Asymchem as Vice President of Medicinal Chemistry

November 1, 2011

TEDA TIANJIN, China, Nov. 1, 2011 /PRNewswire/ — Asymchem Life Science (Tianjin) Co. Ltd., a leading research-based contract manufacturer of advanced intermediates and API’s, and Drug Products, to the pharmaceutical industry, is pleased to announce the recent addition of Dr. Li Qun as Vice President of Medicinal Chemistry as of September 8, 2011. His responsibilities include managing FTE work in medicinal and preclinical synthetic chemistry, based out of TEDA Tianjin.

Dr. Li brings with him a wealth of experience in the practice and management of medicinal and synthetic chemistry. He earned his Ph.D. degree from Beijing University, and did three years of postdoctoral work at Boston University in the U.S. He then moved to Abbott where he worked for 17 years as a medicinal chemist engaged in anti-infective and diabetes research. Dr. Li returned to China in 2008 and served at Bailu as head of new drugs development, and at Chempartner as the scientific head of the ChemExplorer division.

“We are delighted to have Dr. Li Qun join Asymchem to expand our business offerings in the pre-clinical and medicinal chemistry services areas,” says Dr. Hao Hong, CEO of Asymchem.

Asymchem is a leading research-based contract manufacturer specializing in the development and compliant manufacturing (Contract Research and Manufacturing Services) of API’s and Drug Products serving the pharmaceutical industry. With a 15 year track record, Asymchem is committed to the highest level of quality and excellence in the integrated CMC services arena. For further information, please visit the Asymchem website at www.asymchem.com.

SOURCE Asymchem Life Science (Tianjin) Co. Ltd.


Source: PR Newswire